SUPN Q4 2022 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$167M+5.2% YoY

Gross Profit

$144M86.3% margin

Operating Income

$34M20.5% margin

Net Income

$25M15.2% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$28M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$816M

Stockholders' Equity

$886M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$159M	+5.2%
Gross Profit	$144M	$142M	+1.6%
Operating Income	$34M	$6M	+463.0%
Net Income	$25M	$2M	+943.4%

Revenue Segments

Product

$164M49%

Trokendi Xr

$57M17%

GOCOVRI

$29M9%

Oxtellar X R

$27M8%

Qelbree

$24M7%

APOKYN

$18M5%

Manufactured Product, Other

$8M2%

Royalty

$4M1%